Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03818178 · ClinicalTrials.gov registry record · NA

Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids

A NA study of Insulin Resistance, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT03818178: Recruiting NA study of Insulin Resistance, sponsored by Mayo Clinic.

NCT03818178 is a NA study of Insulin Resistance that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03818178, a NA study of Insulin Resistance, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes (T2DM). It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular fatty acid trafficking is responsible for muscle insulin resistance, although it has been shown that raising FFA with Intralipid can cause muscle insulin resistance within 4 hours. The investigators do not understand to what extent the incorporation of FFA into ceramides or diacylglycerols (DG) affect insulin signaling and muscle glucose uptake. The investigators propose to alter the profile and concentrations of FFA of healthy, non-obese adults using an overnight, intra-duodenal palm oil infusion vs. an overnight intra-duodenal Intralipid infusion (both compared to saline control). The investigators will compare the muscle FFA storage into intramyocellular triglyceride, intramyocellular fatty acid trafficking, activation of the insulin signaling pathway and glucose disposal rates, providing the first measure of how different FFA profiles alter muscle FFA trafficking and insulin action at the whole body and cellular/molecular levels. By identifying which steps in the insulin signaling pathway are most affected, the investigators will determine the site-specific effect of ceramides and/or DG on different degrees of insulin resistance. Hypothesis 1: Palm oil infusion will result in abnormal FFA trafficking into intra-myocellular ceramides and abnormal insulin signaling. Hypothesis 2: Intralipid infusion will result in abnormal FFA trafficking into intra-myocellular saturated DG and abnormal insulin signaling.

Primary Outcome

The study involves the use of a hyperinsulinemic, euglycemic clamp to compare fatty acid enrichments in intramyocellular signaling molecules. The first half of the study will be the "pre-clamp" stage. During this stage, volunteers will receive an intravenous infusion of C13-labelled palmitate as a tracer in order for enrichment calculations to be performed pre-clamp. One muscle biopsy will be obtained to measure fatty acid enrichment within intramyocellular ceramides, diacylglycerols, long-chain

Conditions Studied

Interventions

  • OTHER Saline
  • DIETARY_SUPPLEMENT Intralipid
  • DIETARY_SUPPLEMENT Palm Oil Emulsion

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-12-01
Est. Completion 2026-12
Phase NA
Mayo Clinic

2,844 total trials

What NCT03818178 shows while recruiting

NCT03818178 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 3 interventions - of which Saline is the first listed.

NCT03818178 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT03818178 about?

NCT03818178 is a clinical study titled "Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids". Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes (T2DM). It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular fatty acid trafficking is responsible for muscle insulin resistance, although it has been shown that raising FFA with In...

What is the current status of trial NCT03818178?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2018-12-01. Estimated completion is 2026-12.

What conditions does trial NCT03818178 study?

This clinical trial studies the following conditions: Insulin Resistance.

What interventions are being tested in trial NCT03818178?

The interventions under investigation include: Saline (OTHER), Intralipid (DIETARY_SUPPLEMENT), Palm Oil Emulsion (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03818178?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03818178 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03818178's enrollment target sits among peer trials

60 47th of 120 higher than 69 of 120 other Insulin Resistance trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03818178, the US trial registry maintained by the National Library of Medicine. NCT03818178 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.